The selection of hormonal therapy in prostate cancer: who, when, and for how long?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2004.0023PMID 19795609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

  2004cited by this paper
• Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

  2003cited by this paper
• Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.

  2003cited by this paper
• Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.

  2003cited by this paper
• Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.

  2003cited by this paper
• Selective aromatase inhibition for patients with androgen‐independent prostate carcinoma

  2002cited by this paper
• Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.

  2001cited by this paper
• Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma

  2001cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

  2000cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  2000cited by this paper
• A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

  2000cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

  1999cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

  1998cited by this paper
• Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

  1998cited by this paper
• A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

  1998cited by this paper
• Antiandrogen withdrawal syndrome with nilutamide.

  1997cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper
• Megestrol acetate in the treatment of hormone refractory prostate cancer.

  1997cited by this paper
• Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma

  1997cited by this paper
• Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.

  1997cited by this paper
• Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

  1997cited by this paper
• A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.

  1996cited by this paper
• MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS

  1995cited by this paper
• Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

  1995cited by this paper
• Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.

  1995cited by this paper
• Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

  1995cited by this paper
• Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma

  1995cited by this paper
• Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

  1995cited by this paper
• Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.

  1995cited by this paper
• Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.

  1994cited by this paper
• Studies on the human prostatic cancer cell line LNCaP.

  1994cited by this paper
• Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

  1994cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Phase II study of tamoxifen in patients with advanced renal cell carcinoma.

  1980cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer

  2013cites this paper